First GLP‑1 pill approved

The FDA approved the first oral GLP-1 pill for weight loss, an oral semaglutide formulation under the Wegovy brand. (ajmc.com) GLP-1 drugs mimic glucagon-like peptide-1, a gut hormone that signals fullness to the brain and slows stomach emptying. Patients on these medications lose 15-20% of body weight on average over 68 weeks. (nejm.org) Novo Nordisk's oral semaglutide, once daily at 50 mg, showed 15% average weight loss in trials versus 2.4% on placebo. The FDA cleared it based on two phase 3 studies with over 3,000 obese adults without diabetes. (fda.gov) Unlike injectable Wegovy or Ozempic, which require weekly shots, this pill avoids needles and may appeal to needle-phobic patients. About 20-30% of patients discontinue injectables due to injection discomfort. (reuters.com) Oral semaglutide was first approved in 2019 as Rybelsus for type 2 diabetes at lower 3-14 mg doses. This higher 50 mg dose targets chronic weight management, expanding Wegovy's non-injectable options. (fda.gov) Novo Nordisk plans U.S. launch in late 2026 after manufacturing ramps up. Supply shortages have plagued injectables since 2023 demand surged. (bloomberg.com) GLP-1 sales hit $18 billion globally in 2025, led by Novo and Eli Lilly's Mounjaro. Pills could boost adherence and access in primary care, where 70% of prescriptions originate. (statnews.com) Physicians note pills suit patients with mild needle aversion but still demand GI side effects monitoring like nausea. "This expands choices without compromising efficacy," said obesity specialist Dr. Louis Aronne. (endocrinetoday.com) The approval arrives as GLP-1 use climbs to 12% of U.S. adults with obesity. Analysts predict oral versions could capture 20-30% market share from injectables by 2030. (fiercepharma.com)